AYTU BIOPHARMA INC

For the period ended Dec 31, 2023. Filed Feb 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2023 · Filed Feb 14, 2024

AYTU$1.81+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Statements of Operations

(in thousands, except per share data)

Three Months Ended · Six Months Ended
	December 31,		December 31,
	2023	2022	2023	2022
Product revenue, net	$22,934	$26,279	$45,033	$53,934
Cost of sales	6,731	8,986	14,046	18,609
Gross profit	16,203	17,293	30,987	35,325
Operating expenses:
Selling and marketing	6,576	10,560	13,998	20,662
General and administrative	5,439	8,018	12,395	15,340
Research and development	524	1,710	1,128	2,774
Amortization of intangible assets	1,300	1,198	2,606	2,395
Impairment expense	—	2,600	—	2,600
Loss from contingent consideration	—	75	—	230
Total operating expenses	13,839	24,161	30,127	44,001
Income (loss) from operations	2,364	(6,868)	860	(8,676)
Other expense, net	(1,179)	(1,228)	(1,888)	(2,312)
(Loss) gain on derivative warrant liabilities	(577)	1,403	(6,484)	3,594
Income (loss) before income tax	608	(6,693)	(7,512)	(7,394)
Income tax expense	828	—	828	—
Net loss	$(220)	$(6,693)	$(8,340)	$(7,394)
Basic and diluted weighted-average common shares outstanding	5,517,670	3,110,304	5,499,951	2,817,979
Basic and diluted net loss per common share	$(0.04)	$(2.15)	$(1.52)	$(2.62)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.